Prognostic Value of ERCC1, Thymidylate Synthase, and Glutathione S-Transferase π for 5-FU/Oxaliplatin Chemotherapy in Advanced Colorectal Cancer
| Autor: | Ki-Jae Park, Sung-Hyun Kim, Suee Lee, Sung Yong Oh, Jong-Hoon Lee, Dong Mee Lee, Mee-Sook Roh, Hyo-Jin Kim, Hongjo Choi, Hyukchan Kwon, Dae-Cheol Kim |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Lung Neoplasms DNA Repair Organoplatinum Compounds Colorectal cancer medicine.medical_treatment Adenocarcinoma Thymidylate synthase Immunoenzyme Techniques Internal medicine Antineoplastic Combined Chemotherapy Protocols Biomarkers Tumor medicine Humans Peritoneal Neoplasms Aged Retrospective Studies Chemotherapy biology business.industry Liver Neoplasms Hazard ratio Thymidylate Synthase Middle Aged Endonucleases Prognosis medicine.disease Oxaliplatin DNA-Binding Proteins Survival Rate Treatment Outcome Glutathione S-Transferase pi Fluorouracil Lymphatic Metastasis biology.protein Female Bolus (digestion) ERCC1 Colorectal Neoplasms business Follow-Up Studies medicine.drug |
| Zdroj: | American Journal of Clinical Oncology. 32:38-43 |
| ISSN: | 0277-3732 |
| DOI: | 10.1097/coc.0b013e31817be58e |
| Popis: | Background: The aim of this study was to determine whether the expression of the excision repair cross-complementing 1 (ERCC1), thymidylate synthase (TS) and glutathione S-transferase IT (GSTπ) predict clinical outcome in patients with advanced colorectal cancer treated with fluorouracil (5-FU)/ oxaliplatin chemotherapy. Methods: The study population consisted of 70 patients with advanced colorectal cancer (median age, 54 years). Patients were treated with oxaliplatin 85 mg/m 2 as a 2-hour infusion on days 1 plus leucovorin (LV) 20 mg/m 2 over 10 minutes, followed by 5-FU bolus 400 mg/m 2 and a 22-hour continuous infusion of 600 mg/m 2 from day 1 to 2. Treatment was repeated at 2-week intervals. The expression of ERCC1, TS, and GSTπ in primary tumors was examined using immunohistochemistry. Results: ERCC1, TS, and GSTπ were positive in 55.7%, 68.6%, and 71.4% of cases, respectively. Patients without TS expression were more likely to respond to chemotherapy (P = 0.009). There were no significant differences between response to treatment and the ERCC 1 or GSTπ expression pattern (P = 0.768, P = 0.589, respectively). The median overall survival (OS) was significantly longer in patients without ERCC1 expression (P = 0.0474). Patients who were ERCC 1 positive combined with TS positive, or those with ERCC1 positive combined with TS positive and GSTπ positive had a poor OS (P = 0.0017, P = 0.0323, respectively). Multivariate analysis revealed that both ERCC1 and TS expression significantly impacted OS (hazard ratio 1.72, P = 0.023). Conclusion: Immunohistochemical study of ERCC1 and TS may be useful for the prediction of clinical outcome in patients with advanced colorectal cancer treated with 5-FU and oxaliplatin. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|